Axitinib
Vascular Endothelial Growth Factor Receptor (Vegfr) Tyrosine Kinase Inhibitors
Sold as Inlyta
- Drug class
- Vascular Endothelial Growth Factor Receptor (Vegfr) Tyrosine Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 31
Overview
Axitinib is an active pharmaceutical ingredient in the Vascular Endothelial Growth Factor Receptor (Vegfr) Tyrosine Kinase Inhibitors group (L01EK). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 27 | May 1, 2026 |
| EU European Union | EMA | 2 | September 11, 2025 |
| CA Canada | Health Canada | 2 | May 6, 2026 |
GBUnited Kingdom· MHRA
27 products
Uses
Axitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
How to take
EUEuropean Union· EMA
2 products
Uses
Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. 3
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Axitinib. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB200751516 · revised May 1, 2026
- [2]European Medicines Agency · EMEA/H/C/006206 · revised September 11, 2025
- [3]Health Canada (DPD) · 02389630 · revised May 6, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.